Also high antitumor activity of ATRi (ceralasertib) and WEE1i (adavosertib) was shown in non-germinal center DLBCL cell lines, characterized by high MYC expression and CDKN2A/B deletion [138]. Here, MYC is linked to diffuse large B-cell lymphoma.